Biotech company Biogen recently received full approval from the FDA for its drug, lecanemab-irmb, for the treatment of Alzheimer's disease. This marks the first time a drug has been shown to slow the progression of the disease. However, analysts have mixed views on the impact this approval will have on Biogen's stock.

Oppenheimer, a financial services firm, reiterated its outperform rating on Biogen stock and noted that the FDA's decision may lead to greater scrutiny of rival product donanemab from Eli Lilly & Co. On the other hand, Wedbush, an investment firm, maintained its neutral rating on Biogen stock and expressed concerns about the logistics and uptake of the drug.

The FDA's conversion of lecanemab-irmb from accelerated approval to full approval is a significant milestone in the treatment of Alzheimer's disease. The drug targets the underlying disease process and has shown clinical benefit in patients. The approval was based on a phase 3 clinical trial that demonstrated a reduction in decline from baseline on various cognitive and functional scales.

While Biogen's stock initially slid in premarket trading, with analysts taking different views on the approval, the long-term impact remains uncertain. As the market digests the news and more data becomes available, investors will be closely watching how the drug performs in the real world and its potential impact on Biogen's financials.

SKIP STORY